ClinicalTrials.gg
CompletedNCT02091414Updated Oct 29, 2014Results posted

A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.

A Phase 3 interventional study of mycophenolate mofetil (MMF) and cyclosporine A (CsA) in Heart Transplantation, sponsored by Hoffmann-La Roche. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant. The anticipated time on study treatment is 24 weeks.

02

Conditions studied

  • Heart Transplantation
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • patients receiving their first heart transplant (single organ transplant).

Exclusion criteria

Exclusion Criteria:

  • patients with a positive donor-specific cross-match at the time of transplantation;
  • patients with any antibody-treated acute rejection;
  • known to treatment with sirolimus;
  • history of , other than excised non-melanoma skin cancer which has not recurred for 2 years.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    MMF, CsA, Corticosteroids

    Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.

    Drug: mycophenolate mofetil (MMF) · Drug: cyclosporine A (CsA) · Drug: corticosteroids

Interventions

  • 1.0 g PO BID

    Also known as: CellCept

  • Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL

  • Drugcorticosteroids

    As per the practice of each participating center

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week

    Percentage of participants with BPAR of greater than or equal to (≥) International Society of Heart and Lung Transplant (ISHLT) Grade III. The ISHLT graded symptoms on a scale of Grade 0 through VI. Grade 0 equals (=) no rejection. Grade IA = regional (perivascular or interstitial) infiltration and no necrosis, and grade IB = dissemination but little infiltration and no necrosis. Grade II = 1 focus of invasive infiltration with or without (+/-) associated cardiomyocyte necrosis. Grade IIIA = 2 or more foci of invasive infiltration +/- associated cardiomyocyte necrosis, and grade IIIB = diffuse inflammatory pathological changes associated with cardiomyocyte necrosis. Grade IV = diffuse, infiltrative multi-foci +/- edema; +/- hemorrhage; and +/-vasculitis.

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Secondary outcomes

  1. Percentage of Participants With Graft Loss Within 24 Weeks of Transplantation

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  2. Percentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  3. Percentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  4. Percentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  5. Percentage of Participants With Normal Serum Creatinine and Blood Urea Nitrogen (BUN) Values At Baseline (BL) And During Treatment

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  6. Percentage of Participants With Normal Serum Creatinine and BUN Values at Baseline and Abnormal Values During Treatment

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  7. Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and Normal Values During Treatment

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  8. Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and During Treatment

    Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

07

Results

Posted Oct 29, 2014

Participant flow

Participant flow — Overall Study
MilestoneMycophenolate Mofetil (MMF) Plus (+) Cyclosporine A (CsA)
Started36
Completed32
Not completed4
Withdrew: Withdrawal by subject2
Withdrew: Death2

Outcome measures

PrimaryPercentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week

Percentage of participants with BPAR of greater than or equal to (≥) International Society of Heart and Lung Transplant (ISHLT) Grade III. The ISHLT graded symptoms on a scale of Grade 0 through VI. Grade 0 equals (=) no rejection. Grade IA = regional (perivascular or interstitial) infiltration and no necrosis, and grade IB = dissemination but little infiltration and no necrosis. Grade II = 1 focus of invasive infiltration with or without (+/-) associated cardiomyocyte necrosis. Grade IIIA = 2 or more foci of invasive infiltration +/- associated cardiomyocyte necrosis, and grade IIIB = diffuse inflammatory pathological changes associated with cardiomyocyte necrosis. Grade IV = diffuse, infiltrative multi-foci +/- edema; +/- hemorrhage; and +/-vasculitis.

Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week
percentage of participantsMMF + CsA
Day 10.0 (0.00 to 0.00)
Week 10.0 (0.00 to 0.00)
Week 22.78 (0.00 to 8.42)
Week 42.78 (0.00 to 8.42)
Week 82.78 (0.00 to 8.42)
Week 122.78 (0.00 to 8.42)
Week 162.78 (0.00 to 8.42)
Week 202.78 (0.00 to 8.42)
Week 242.78 (0.00 to 8.42)
SecondaryPercentage of Participants With Graft Loss Within 24 Weeks of Transplantation
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Graft Loss Within 24 Weeks of Transplantation
percentage of participantsMMF + CsA
Percentage of Participants With Graft Loss Within 24 Weeks of Transplantation0.0
SecondaryPercentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation
percentage of participantsMMF + CsA
Percentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation0.0
SecondaryPercentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation
percentage of participantsMMF + CsA
Percentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation13.89 (2.02 to 25.76)
SecondaryPercentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation
percentage of participantsMMF + CsA
Percentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation0.0
SecondaryPercentage of Participants With Normal Serum Creatinine and Blood Urea Nitrogen (BUN) Values At Baseline (BL) And During Treatment
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Normal Serum Creatinine and Blood Urea Nitrogen (BUN) Values At Baseline (BL) And During Treatment
percentage of participantsMMF + CsA
Serum creatinine47.22
BUN8.33
SecondaryPercentage of Participants With Normal Serum Creatinine and BUN Values at Baseline and Abnormal Values During Treatment
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Normal Serum Creatinine and BUN Values at Baseline and Abnormal Values During Treatment
percentage of participantsMMF + CsA
Serum creatinine22.22
BUN16.67
SecondaryPercentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and Normal Values During Treatment
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and Normal Values During Treatment
percentage of participantsMMF + CsA
Serum creatinine16.67
BUN2.78
SecondaryPercentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and During Treatment
Time frame:
Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and During Treatment
percentage of participantsMMF + CsA
Serum creatinine13.89
BUN72.22

Adverse events

Collected over Adverse events were assessed at Day 1, and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MMF + CsA—2/36 (5.6%)36/36 (100%)
Most frequent serious events
Most frequent serious events
EventMMF + CsA
Multiple organ failureGeneral disorders1/36
Cardiac arrestCardiac disorders1/36
Most frequent other events
Showing 10 of 54
Most frequent other events
EventMMF + CsA
CoughRespiratory, thoracic and mediastinal disorders17/36
Elevated blood sugarInvestigations14/36
HyperglycemiaMetabolism and nutrition disorders14/36
TachycardiaCardiac disorders8/36
HypertensionVascular disorders8/36
InsomniaPsychiatric disorders7/36
Elevated blood lipidsInvestigations7/36
Elevated serum creatinineInvestigations7/36
Elevated alanine aminotransferaseInvestigations7/36
Abnormal liver function testsInvestigations7/36

Baseline characteristics

Intent-to-treat (ITT) population: all enrolled participants who recieved at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)MMF + CsA
Mean44.83 ± 11.89
Sex: Female, Male
Sex: Female, Male(Participants)MMF + CsA
Female8
Male28
08

Study locations

3 sites
  • Beijing, 100029, China
  • Fuzhou, 350001, China
  • Shanghai, 200032, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2014
First posted
Mar 19, 2014
Start
Aug 2006
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Oct 29, 2014
Last update
Oct 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02091414
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Aug 2006
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Oct 29, 2014
Last update
Oct 29, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mycophenolic Acid · Cyclosporine

Start the discussion